ClinicalTrialsFinder
RecruitingPhase 4NCT07468513

Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.

Sponsor

Menzies School of Health Research

Enrollment

100 participants

Start Date

May 17, 2024

Study Type

INTERVENTIONAL

Conditions

Vivax malariaG6PD Deficiency

Summary

A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\<30% activity)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). and a drug called Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days for people with g6pd deficiency and vivax malaria. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPatients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days

Primaquine 1mg/kg/day for 7 days

DRUGPatients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose).

8 weekly Primaquine (0.75mg/kg dose).

Locations(4)

Dr Marcus Lacerda

Manaus, Brazil

Arba Minch General Hospital

Arba Minch, Ethiopia

Dr Moses Laman and Dr Brioni Moore

Alexishafen, Madang Province, Papua New Guinea

Papua New Guinea Institute of Medical Research

Port Moresby, Magang, Papua New Guinea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07468513

Related Trials

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

NCT061487924 locations